WellDoc
Digital Solutions to Combat Chronic Diseases

As digital healthcare completes its migration to a mobile-centric world, profound innovations are moving full speed ahead toward solutions that aid in chronic care diagnosis, treatment, and management. “There’s a lot of noise—activities, press releases, and investments—and a lot of partnerships going on in digital health,” says Kevin McRaith, chief executive officer of WellDoc.

WellDoc, a digital health company based in Columbia, Md., is an active participant in several such key partnerships. The Columbia, Md.–based company was founded by an endocrinologist with her vision to create an engaging, effective digital health solution for adults with type 2 diabetes. More than a decade later, WellDoc has established itself as a leader in the field of digital health.

The company’s flagship product BlueStar^®, is a FDA-cleared, in-app diabetes coach that provides individualized real-time guidance for adults with type 2 diabetes. BlueStar enables people to make better decisions about their diabetes management on their own, while connecting and aligning them to their health care teams.

BlueStar^®, is a FDA-cleared, in-app diabetes coach that provides individualized real-time guidance for adults with type 2 diabetes

BlueStar has been shown to provide proven clinical and real-world outcomes, which have been published in several peer-reviewed journals. These outcomes—including significant reductions in A1C, as well as fewer hospitalizations and emergency room visits—can help drive cost savings in diabetes care.

As a digital health company built on a life science business model, WellDoc continues to expand upon the core features of BlueStar that allow the app to deliver improved clinical outcomes through a proprietary expert system. This system maps out the appropriate interventions for patients in the moment, based on individual events, longitudinal event patterns and patient behaviors related to multiple aspects of diabetes care—for example, blood glucose testing, food choices, exercise, sleep, and medication adherence.

Although the company currently focuses on diabetes management, the company plans to expand its novel platform across different chronic disease domains. To that end, McRaith says WellDoc has been establishing strategic partnerships to ensure it can effectively advance its mission. In the case of BlueStar, the company recently announced a partnership with Samsung Health to offer a direct-to-consumer diabetes management app. WellDoc has also established a commercial partnership with LifeScan, a Johnson & Johnson diabetes care company, to deliver integrative digital therapeutic solutions for adults with type 2 diabetes. Additionally, WellDoc recently began collaborating with the American Association of Diabetes Educators (AADE) by developing the first of its kind digital diabetes curriculum based on the AADE’s Healthy 7 behaviors.